AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportSchrödinger vs Atomwise
Schrödinger
VS
Atomwise
Verdict by Category
Detailed Comparison
Feature
Schrödinger
Atomwise
Pricing
PaidSchrödinger offers software through subscription licenses and hosted cloud access.
Enterprise pharma customers access the full suite (Maestro, Glide, FEP+, Jaguar, Prime, and Bunsen AI) through annual software licensing agreements. Pricing is tiered by organization size, usage volume, and modules required. Enterprise software ACV reached $198.5M in 2025.
Academic and government institutions access Schrödinger tools through educational licensing at significantly reduced rates. Cloud-hosted subscriptions are also available for teams preferring managed infrastructure.
Drug discovery partnerships with pharma (BMS, Sanofi, Takeda) are structured as sponsored research and co-development agreements with milestone-based payments. Contact Schrödinger through schrodinger.com for enterprise pricing, academic licenses, or partnership inquiries.
CustomAtomwise operates through enterprise partnership and co-development agreements — there is no self-serve access or published pricing.
Collaboration types include: sponsored research agreements (pharma/biotech pays Atomwise to run AI-powered hit discovery campaigns), co-development partnerships (shared IP and milestone/royalty structures), and academic program access for universities through the ATOM initiative.
New CEO Steve Worland is also steering Atomwise toward an internal proprietary drug pipeline, which will generate revenue through future licensing and partnering deals as candidates mature into preclinical and clinical stages.
Contact Atomwise through atomwise.com for partnership and collaboration inquiries.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
Physics-based drug discovery with Bunsen AI co-scientist — trusted by 500+ pharma companies worldwide
Deep learning for structure-based drug discovery — AtomNet screens 16B+ compounds to find hits for any disease target
Schrödinger Pros & Cons
Pros
- 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
- Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
- FEP+ delivers industry-leading accuracy in binding affinity prediction
- NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
- 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
- Materials science applications extend reach to battery, semiconductor, and chemical sectors
- Cloud-hosted subscriptions eliminate on-premise infrastructure burden
Cons
- Software is expensive — enterprise pricing puts it out of reach for smaller labs
- Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
- Drug discovery segment revenue is milestone-dependent and lumpy
- Platform learning curve is steep without computational chemistry background
- Competition from newer, purely AI-native platforms is intensifying
Atomwise Pros & Cons
Pros
- Invented deep learning for structure-based drug discovery in 2012 — true pioneer in the field
- AtomNet screens 16B+ compounds in under 2 days — fastest virtual screening at this scale
- 775+ collaborations and 250+ partners — most validated partnership network in AI drug discovery
- Tackles undruggable targets that traditional methods can't address
- Strong academic program: 40+ universities including Harvard, Stanford, and Duke
- New Foundation Model announced 2026 — next-generation AI for molecular discovery
- $226M+ raised from DCVC, Khosla, Y Combinator, Tencent, B Capital, and Baidu
Cons
- Early-stage company — no FDA-approved drugs from the platform yet
- Shifting focus from platform licensing to proprietary pipeline adds execution risk
- Smaller team (~100-250 employees) compared to larger AI drug discovery peers
- Revenue still modest at $5-25M range — pre-commercial stage
- Deep tech focus means long timelines before patient impact is realized